Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilvegostomig in Advanced or Metastatic NSCLC
NCT04995523Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Sep 2021
- Primary completion
- Aug 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 16
01
Overview
A Phase 2 trial of rilvegostomig in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Sep 2021; status: active, not recruiting.
02
Drugs
rilvegostomig
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04995523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04995523.